P1.02-04 The EGFR Resisters Lung Cancer Group: A Patient-Driven Initiative to Understand and Improve Treatments for EGFR+ Lung Cancer

Hydroxyurea has been adequately evaluated in 27 patients with inoperable or advanced lung cancer (group A). The drug was also given to 13 patients with miscellaneous metastatic solid tumors (group B). Four different dosages of hydroxyurea were administered: 40 mg/kg/day p.o. (15 patients of group A and 7 patients of group B); 10 mg/kg/day i.v. (3 patients of group A and 1 patient of group B); 100 mg/kg/week (3 patients of group A and 2 patients of group B); 100 mg/kg i.v. on alternate days (6 patients of group A and 3 patients of group B). The total daily dose was given in two administrations with an interval of 12 hours. None of the patients had been previously treated with radiotherapy or chemotherapy; their performance status was not less than 40. Subjective and objective responses, evaluated on the Karnofsky's categories, were seen in patients with advanced lung cancer, but only one patient of the miscellaneous group showed an objective response to hydroxyurea. The therapeutic responses were achieved in group A with dosages of 40 mg/kg/day p.o. (5/15 cases) and of 100 mg/kg i.v. on alternate days (4/6 cases). Relief of symptoms and objective regressions were short-lived. No maintenance treatment in responsive cases was given. There was no definite change in the basic course of the disease. The other patients treated respectively with 10 mg/kg/day and with 100 mg/kg/week were very few and received a smaller total dose of hydroxyurea. Bone marrow toxicity occurred mainly with patients receiving higher doses of hydroxyurea (40 mg/kg by mouth and 100 mg/kg i.v. on alternate days respectively). In these patients progressive leukopenia and anemia developed in almost every case, often requiring multiple blood transfusions. Megaloblastosis was checked in 3 cases. Five patients after 2–3 weeks of treatment had nasal bleeding, which disappeared spontaneously after 3–6 days. Only 2 patients, while receiving hydroxyurea by mouth, complained of nausea and epigastric distress and the drug was discontinued temporarily. Two patients showed a mild hyperuricemia after the first week of treatment. The administration of intravenous hydroxyurea at the dose of 100 mg/kg on alternate days in lung cancer deserves a more extensive trial.

Download Full-text

Circulating and local nuclear expression of survivin and fibulin-3 genes in discriminating benign from malignant respiratory diseases: correlation analysis

Bioscience Reports ◽

10.1042/bsr20203097 ◽

2020 ◽

Author(s):

Mohammed H. Hassan ◽

Sawsan Abuhamdah ◽

Mohamed Abdel-Bary ◽

Mohammed Wahman ◽

Tarek Hamdy Abd-Elhamid ◽

...

Keyword(s):

Lung Cancer ◽

Respiratory Diseases ◽

Serum Levels ◽

Control Group ◽

Expression Levels ◽

Pleural Diseases ◽

Cancer Group ◽

Group A ◽

Group B ◽

Group D

Survivin is an inhibitor of apoptosis as well as a promoter of cell proliferation. Fibulin-3 is a matrix glycoprotein that displays potential for tumor suppression or propagation. This study aimed to validate the expression levels of survivin and fibulin-3 in benign and malignant respiratory diseases. This case–control study included 219 patients categorized into five groups. Group A included 63 patients with lung cancer, group B included 63 patients with various benign lung diseases, group D included 45 patients with malignant pleural mesothelioma (MPM), and group E included 48 patients with various benign pleural diseases. Group C included 60 healthy individuals (control group). Serum survivin and fibulin-3 levels were measured by ELISA, whereas their nuclear expressions in the lung and pleura were assessed via Western blot analysis. The results showed significantly higher survivin serum levels and significantly lower fibulin-3 levels in group A compared with in group B and controls (p<0.001). There were significantly higher serum levels of survivin and fibulin-3 in group D compared with in group E and controls (p<0.001), consistent with observed nuclear survivin and fibulin-3 expression levels. Fibulin-3 was determined to have higher value than survivin in discriminating lung cancer from MPM (p˂0.05). Survivin and fibulin-3 could be useful diagnostic markers for lung and pleural cancers, and fibulin-3 expression was particularly useful in differentiating lung cancer from MPM. Trial registration: ClinicalTrials.gov Identifier: NCT04413292: https://clinicaltrials.gov/ct2/show/NCT04413292, retrospectively registered.

Download Full-text

Survival Impact of Aggressive Treatment and PD-L1 Expression in Oligometastatic NSCLC

Current Oncology ◽

10.3390/curroncol28010059 ◽

2021 ◽

Vol 28 (1) ◽

pp. 593-605

Author(s):

Camille Gauvin ◽

Vimal Krishnan ◽

Imane Kaci ◽

Danh Tran-Thanh ◽

Karine Bédard ◽

...

Keyword(s):

Lung Cancer ◽

Cell Death ◽

Treatment Group ◽

Programmed Cell Death ◽

Prognostic Impact ◽

Aggressive Treatment ◽

Palliative Approach ◽

Oligometastatic Disease ◽

Group A ◽

Group B

Background: Studies have shown that aggressive treatment of non-small cell lung cancer (NSCLC) with oligometastatic disease improves the overall survival (OS) compared to a palliative approach and some immunotherapy checkpoint inhibitors, such as anti-programmed cell death ligand 1 (PD-L1), anti-programmed cell death protein 1 (PD-1), and T-Lymphocyte-associated antigen 4 (CTLA-4) inhibitors are now part of the standard of care for advanced NSCLC. However, the prognostic impact of PD-L1 expression in the oligometastatic setting remains unknown. Methods: Patients with oligometastatic NSCLC were identified from the patient database of the Centre hospitalier de l’Université de Montréal (CHUM). “Oligometastatic disease” definition chosen is one synchronous metastasis based on the M1b staging of the eight IASLC (The International Association for the Study of Lung Cancer) Classification (within sixth months of diagnosis) or up to three cerebral metastasis based on the methodology of the previous major phase II randomized study of Gomez et al. We compared the OS between patients receiving aggressive treatment at both metastatic and primary sites (Group A) and patients receiving non-aggressive treatment (Group B). Subgroup analysis was performed using tumor PD-L1 expression. Results: Among 643 metastatic NSCLC patients, we identified 67 patients with oligometastasis (10%). Median follow-up was 13.3 months. Twenty-nine patients (43%) received radical treatment at metastatic and primary sites (Group A), and 38 patients (57%) received non-aggressive treatment (Group B). The median OS (mOS) of Group A was significantly longer than for Group B (26 months vs. 5 months, p = 0.0001). Median progression-free survival (mPFS) of Group A was superior than Group B (17.5 months vs. 3.4 months, p = 0.0001). This difference was still significant when controlled for primary tumor staging: stage I (p = 0.316), stage II (p = 0.024), and stage III (p = 0.001). In the cohort of patients who were not treated with PD-L1 inhibitors, PD-L1 expression negatively correlated with mOS. Conclusions: Aggressive treatments of oligometastatic NSCLC significantly improve mOS and mPFS compared to a more palliative approach. PD-L1 expression is a negative prognostic factor which suggests a possible role for immunotherapy in this setting.

Download Full-text

Effects of depression and anxiety on mortality in a mixed cancer group: a longitudinal approach using standardised diagnostic interviews

Psycho-Oncology ◽

10.1002/pon.3714 ◽

2014 ◽

Vol 24 (6) ◽

pp. 718-725 ◽

Cited By ~ 30

Author(s):

Caryn Mei Hsien Chan ◽

Wan Azman Wan Ahmad ◽

Mastura MD Yusof ◽

Gwo-Fuang Ho ◽

Edward Krupat

Keyword(s):

Depression And Anxiety ◽

Cancer Group ◽

Diagnostic Interviews ◽

Longitudinal Approach ◽

Group A

Download Full-text

P-797 Combination chemotherapy including topotecan concurrentlywith twice-daily radiotherapy in limited SCLC. A phase II trial of the Danish Oncological Lung Cancer Group (DOLG)

Lung Cancer ◽

10.1016/s0169-5002(05)81290-5 ◽

2005 ◽

Vol 49 ◽

pp. S329

Author(s):

M. Sorensen ◽

U. Lassen ◽

S. Langer ◽

T. Palshof ◽

B. Bjerregaard

Keyword(s):

Lung Cancer ◽

Phase Ii ◽

Combination Chemotherapy ◽

Phase Ii Trial ◽

Cancer Group

Download Full-text

9088 POSTER Erlotinib as Frontline Treatment for Elderly Patients With Advanced Non-Small-Cell Lung Cancer (NSCLC) and Non-Squamous Histology – Results of a Galician Lung Cancer Group (GGCP044/09 Study) Grupo Galego De Cancro De Pulmon (GGCP)

European Journal of Cancer ◽

10.1016/s0959-8049(11)72400-5 ◽

2011 ◽

Vol 47 ◽

pp. S619

Author(s):

J.L. Fírvida ◽

S. Vázquez ◽

J. Casal ◽

A. Fernández ◽

S. Varela ◽

...

Keyword(s):

Lung Cancer ◽

Elderly Patients ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Small Cell Lung ◽

Cancer Group ◽

Frontline Treatment

Download Full-text

Evaluation of sputum cytology in mass screening program for lung cancer: With special reference to the method and the results of sputum cytology in the Cooperative Early Lung Cancer Group and comparison with those of the Osaka Lung Project.

The Journal of the Japanese Society of Clinical Cytology ◽

10.5795/jjscc.34.1210 ◽

1995 ◽

Vol 34 (6) ◽

pp. 1210-1217

Author(s):

Minoru MATSUDA

Keyword(s):

Lung Cancer ◽

Special Reference ◽

Mass Screening ◽

Screening Program ◽

Sputum Cytology ◽

Cancer Group ◽

Early Lung Cancer

Download Full-text

Diagnostic Value of Imaging Combined With Tumor Markers in Early Detection of Lung Cancer

Frontiers in Surgery ◽

10.3389/fsurg.2021.694210 ◽

2021 ◽

Vol 8 ◽

Author(s):

Su-Ju Wei ◽

Li-Ping Wang ◽

Jun-Yan Wang ◽

Jing-Xu Ma ◽

Feng-Bin Chuan ◽

...

Keyword(s):

Lung Cancer ◽

Early Detection ◽

Tumor Markers ◽

Cancer Diagnosis ◽

Diagnostic Value ◽

Diagnostic Methods ◽

Lung Cancer Diagnosis ◽

Early Lung Cancer ◽

Group A ◽

Group B

Objective: The objective of this research is to explore the diagnostic value of imaging plus tumor markers in the early detection of lung cancer.Methods: Sixty patients with lung cancer treated in our hospital from January 2018 to January 2019 were selected as group A. They were matched with 60 patients with benign lung disease as group B and 60 healthy subjects examined in our hospital as group C. The carcino-embryonic antigen (CEA), CYFRA21-1, and neuron-specific enolase (NSE) were assessed, and the diagnostic value of tumor markers plus imaging in lung cancer diagnosis was explored.Results: The CEA, CYFRA21-1, and NSE in group A were evidently superior to those in groups B and C, and those in group B were superior to those in group C (all P < 0.001). CEA had the highest sensitivity (56.7%), and NSE had the highest specificity (93.3%). The tumor markers plus imaging had the highest sensitivity for different types of lung cancer, and the sensitivity to early lung cancer (90%) was superior to other diagnostic methods (P < 0.05).Conclusion: The tumor markers plus imaging is of great significance in early lung cancer diagnosis and provides a reference for judging the pathological classification.

Download Full-text